NanoBio Interfaces: Opportunities and Challenges of Protein Corona
Nanoparticles (NPs) are becoming increasingly promising tools for medical diagnostics and therapeutics. Despite the advances in their biomedical applications and numerous publications, fewer than expected NPs have made it to clinical trials and even fewer have reached clinical practice. This wide gap between bench discoveries and clinical applications is, at least in part, because of our limited understanding of the nanobiointerfaces. In physiological environments, NPs are coated by a ‘protein corona’, critically affecting physiological and therapeutic responses. The talk is aimed to provide an overview on the importance of protein corona in nanomedicine together with its opportunities and challenges. Developments of quantitative models to predict biological interactions and how they offer new opportunities for the clinical translation of NPs will be also covered in the talk.
Morteza Mahmoudi is an instructor at Brigham and Women’s Hospital and Harvard Medical School. He has authored >175 papers (>14,500 citations) and holds>10 issued/pending US and International patents. His specific research interest is in nanomedicine and regenerative medicine for the development of new nano-based platforms for prevention/treatment of life-threatening conditions such as cardiomyopathy, cancer, and neurodegenerative diseases.